Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
Rhea-AI Summary
Pliant Therapeutics (Nasdaq: PLRX) will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference in a virtual format on February 25-26, 2026. A fireside chat featuring Bernard Coulie, M.D., Ph.D., CEO, and Keith Cummings, M.D., CFO, is scheduled for Feb 25, 2026 at 2:40 p.m. ET.
According to the company, the live webcast will be accessible via Pliant’s Investor Relations events page, and a replay will be archived on the Pliant website for 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – PLRX
In the Feb 23 session, PLRX declined 0.81%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 04 | Clinical data update | Positive | -15.6% | Interim Phase 1 PLN-101095 data showed responses in ICI-refractory tumors. |
| Dec 01 | Conference participation | Neutral | -5.0% | Announcement of participation and fireside chat at Piper Sandler conference. |
| Nov 06 | Earnings and update | Positive | -6.7% | Q3 2025 financials, PLN-101095 enrollment completion, and cash position disclosure. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, including positive clinical data and a corporate update, was followed by negative 24-hour price reactions, suggesting a pattern of selloffs on positive or neutral headlines.
Over the last few months, PLRX has released several material updates. On Nov 6, 2025, a Q3 2025 update highlighted lower R&D and G&A expenses and strong cash of $243.3M, yet shares fell 6.71%. On Dec 4, 2025, encouraging Phase 1 data for PLN-101095, including a 15-month median time on treatment for responders, led to a 15.58% decline. A conference participation notice on Dec 1, 2025 also saw a 4.97% drop, echoing today’s conference-focused announcement.
Key Terms
integrin-based therapeutics medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference being held in a virtual format February 25-26, 2026.
Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer and Keith Cummings, M.D., Chief Financial Officer, will participate in a fireside chat on Wednesday, February 25, 2026, at 2:40 p.m. Eastern Time.
Interested parties may access the live webcast of the fireside chat by visiting here or the Investor Relations’ Events & Presentation page of Pliant’s website. The webcast replay will be archived on the Pliant website for 30 days following the conclusion of the event.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. The Company’s lead program is PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. Pliant’s early-stage platform includes preclinical research focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules. For additional information, please visit: www.PliantRx.com. Follow us on social media X, LinkedIn and Facebook.
Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com
